Adamis Pharmaceuticals (ADMP) could benefit from rival Mylan's (MYL) high price of EpiPens as its own product is reportedly close to approval. Adamis has an epinephrine pre-filled syringe that may be better than the EpiPen, even apart from the price controversy.
Price target: $10
No comments:
Post a Comment